Tweets
Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S.
https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over the decades. Prevalence of proteinuria also did not change at 5 and 10 yrs after dx. Earlier use of HCQ has not led to a ⬇️in lupus nephritis. @RheumNow #ACRbest
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 5 months ago
Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies:
- spontaneous loss rate comparable to non-disease controls
- no stillbirths
- preterm similar to disease controls
Plenty positive for CZP in pregnancy!
#ACR24 ABST0805 @RheumNow https://t.co/XCRYsioxC0
David Liew @drdavidliew ( View Tweet )
1 year 5 months ago
A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA).
Key findings:
- Among patients initially at LDA, achieving remission (CDAI ≤2.8) led to significantly better functional outcomes and reduced durable medical equipment… https://t.co/SNPKlRieur https://t.co/YIQNMf3Oap
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
We know most preexisting autoimmune disease is very mangaeable when checkpoint inhibitors are needed.
So great to see that, in the VA, autoimmune disease pts largely haven't missed out on potentially lifesaving cancer immunotherapy.
Keep on reassuring!
#ACR24 ABST1985 @RheumNow https://t.co/ApOACBLi4K
David Liew @drdavidliew ( View Tweet )
1 year 5 months ago
Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 5 months ago
I have no doubt many of our RA patients will take GLP-1 agonists in the future.
Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain.
Will be fascinating to see what it does for grumbling disease activity!
#ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A
David Liew @drdavidliew ( View Tweet )
1 year 5 months ago
Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches.
https://t.co/ZInKmVS2Gn
@RheumNow #ACR24
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 5 months ago
What is #healthliteracy? Why is it important for our patients with #RMDs?
Come to poster 1913 today at #ACR24 to find out about health literacy & outcomes in #InflammatoryArthritis
For more information on this important topic, read my article @RheumNow
https://t.co/llWs5aYtpK
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 5 months ago
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Instead of just JAKi, why don't we look at all our RA meds and MACE risk
FAERS data & reporting odds ratios here: all the caveats of voluntary reporting, so don't put too much weight, but...
prednisone. Don't forget pred is really not great for MACE!
#ACR24 ABST1981 @RheumNow https://t.co/L9SlPZF2Jd
David Liew @drdavidliew ( View Tweet )
1 year 5 months ago
Lung ultrasound for ILD in SSc/IIM would be great, no radiation and by the bedside - but a lot of skill required to interpret in reality.
Maybe AI/computer vision can come to the rescue?
Some nice models @StanfordRheum - will be watching this space!
#ACR24 ABST1965 @RheumNow https://t.co/0uXBSVSE4c
David Liew @drdavidliew ( View Tweet )
1 year 5 months ago
